Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19773391 | 0.80 | CYP19A1 (0.52) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL9858404 | 0.77 | CYP2D6 (0.38) | CYP3A4CYP1A2KIF11 | |
| SCHEMBL29700962 | 0.74 | CYP19A1 (0.55) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL8606938 | 0.74 | CYP19A1 (0.55) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL27900809 | 0.73 | CYP19A1 (0.53) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL12713543 | 0.72 | CYP19A1 (0.52) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL28803515 | 0.71 | CYP19A1 (0.51) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL28442672 | 0.71 | CYP19A1 (0.51) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL11878647 | 0.71 | CYP19A1 (0.51) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL29583584 | 0.71 | KIF11 (0.61) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324410-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-12-04 | — | — | US | disclosed |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-09-20 | — | — | US | disclosed |
| WO-2009141738-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | CYP3A4 2281/4885LMNA 153/4885CYP1A2 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.